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Objective: To examine the dose-dependent relationship of different types of statins
with the occurrence of major depressive disorder (MDD) and prescription of
antidepressant medication.
Methods: This cross-sectional study used medical claims data for the general Austrian
population (n = 7,481,168) to identify all statin-treated patients. We analyzed all patients
with MDD undergoing statin treatment and calculated the average defined daily dose
for six different types of statins. In a sub-analysis conducted independently of inpatient
care, we investigated all patients on antidepressant medication (statin-treated patients:
n = 98,913; non-statin-treated patients: n = 789,683). Multivariate logistic regression
analyses were conducted to calculate the risk of diagnosed MDD and prescription of
antidepressant medication in patients treated with different types of statins and dosages
compared to non-statin-treated patients.
Results: In this study, there was an overrepresentation of MDD in statin-treated
patients when compared to non-statin-treated patients (OR: 1.22, 95% CI: 1.20–1.25).
However, there was a dose dependent relationship between statins and diagnosis of
MDD. Compared to controls, the ORs of MDD were lower for low-dose statin-treated
patients (simvastatin>0–<=10 mg:OR: 0.59, 95% CI: 0.54–0.64; atorvastatin>0–<=10
mg:OR:0.65, 95%CI: 0.59–0.70; rosuvastatin>0–<=10 mg:OR: 0.68, 95% CI:
0.53–0.85). In higher statin dosages there was an overrepresentation of MDD
(simvastatin>40–<=60 mg:OR: 2.42, 95% CI: 2.18–2.70, >60–80 mg:OR: 5.27, 95%
CI: 4.21–6.60; atorvastatin>40–<=60 mg:OR: 2.71, 95% CI: 1.98–3.72, >60–<=80
mg:OR: 3.73, 95% CI: 2.22–6.28; rosuvastatin>20–<=40 mg:OR: 2.09, 95% CI:
1.31–3.34). The results were confirmed in a sex-specific analysis and in a cohort of
patients taking antidepressants, prescribed independently of inpatient care.
Conclusions: This study shows that it is important to carefully re-investigate the
relationship between statins and MDD. High-dose statin treatment was related to an
overrepresentation, low-dose statin treatment to an underrepresentation of MDD.
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INTRODUCTION
Statins rank among the most-prescribed drugs worldwide and
have significant lipid-lowering effects and hence they are
usually prescribed to prevent and treat cardiovascular disease
(CVD). Recently published guidelines of the European Society
of Cardiology (ESC/EAS) recommend that high-risk patients,
such as patients with type-2 diabetes with organ damage
or patients with CVD, should have low-density lipoprotein
cholesterol (LDL-cholesterol) levels lower than 55 mg/dl (1). The
main mechanism of statins is inhibition of 3-hydroxy-3-methyl-
glutaryl-coenenzyme A reductase (HMG-CoA reductase), which
in turn inhibits synthesis of mevalonic acid, the main substrate
for the synthesis of cholesterol. Cholesterol itself is the basic
substance for the synthesis of essential hormones such as sex
hormones or vitamin D. In this context, earlier studies have
shown that statins can lower the concentrations of sex hormones
for instance (2–5).
A connection between sex hormones and depression has also
been demonstrated by earlier studies. Low levels of estrogen
have been associated with depression in women (6–10) and
withdrawal of hormone therapy for remitted perimenopausal
depression has been linked to recurrence of depressive symptoms
(7). Similar results have been shown for low testosterone levels
in men (11–13). Earlier studies report associations between
low levels of cholesterol and consequently statin usage and
depression, as well as related symptoms such as lowered mood,
aggression and suicidality (14–17). A potential mechanism for
these associations is impaired serotonin signaling, as cholesterol
is required for serotonin 1A receptor function (18–20) and hence
downregulation of the serotonin 1A receptor has been linked to
mood disorders such as depression (21).
More recently, the neuroinflammation hypothesis for
depression has gained traction, also pointing to antidepressant
effects of anti-inflammatory agents such as statins (22). Along
these lines, some studies report a protective effect of statins on the
development of depression (22–29). One of the major problems
of the existing literature is that especially the relationship
between high-dose statin treatment and MDD has yet to be
investigated in detail. Data on the relationship between high-
dose statin treatment and MDD in randomized controlled trials
(RCTs) are particularly sparse and hence the existing literature
does not clearly demonstrate that statins have an antidepressant
effect, which is the main reason why they are not considered in
antidepressant therapy (30). Given the paucity of data, the aim
of the present study was to investigate the relationship between
statins of different types and dosages and MDD.
METHODS
Study Design
This cross-sectional retrospective analysis investigated medical
claims data for the general Austrian population. Two groups
[patients (1) with and (2) without statin treatment] were
compared in order to investigate the relationship between statin
treatment and MDD.
Patient Population
In the present analysis, health data were investigated for
all Austrians receiving health care services, i.e., ∼97% of
the population. These data include all diagnoses recorded
during a hospital stay and data for all drug prescriptions
exceeding a prescription charge of EUR 4.70. All patients
alive during the observational period from January 2006
to December 2007 (n= 7,945,775) were analyzed, and age
and sex were noted. Patients born in these years or aged
>90 were excluded. The final study cohort consisted of
7,481,168 patients (3,507,903 males; 3,973,265 females). Medical
prescriptions during the study period were analyzed using
the Anatomical Therapeutic Chemical (ATC) Classification
System codes.
Characterization of Patients With MDD
We identified all patients diagnosed with MDD during hospital
stays by using primary and secondary diagnoses, as defined
by the International Classification of Diseases, 10th revision
(ICD-10), codes. We classified patients as having MDD if
they had a primary or secondary diagnosis of F32 (major
depressive disorder, single episode) or F33 (major depressive
disorder, recurrent). In order to strengthen our results, we
performed a sub-analysis in which we investigated all patients
who had been prescribed antidepressants (n = 888,596),
irrespective of inpatient hospital stays. In another sub-analysis,
we considered only patients with at least one hospital stay
(n= 2,011,334), i.e., for whom diagnoses could in principle have
been recorded.
Characterization of Statin-Treated Patients
and the Control Group
The statin-treated group consisted of patients prescribed one
of the following six statins in at least four different quarters
of a year (representing the common prescription procedure
in Austria and patients’ compliance) during the observational
period: simvastatin (ATC-code:C10AA01), lovastatin (ATC-
code:C10AA02), pravastatin (ATC-code:C10AA03), fluvastatin
(ATC-code:C10AA04), atorvastatin (ATC-code:C10AA05), and
rosuvastatin (ATC-code:C10AA07). Patients who had been
prescribed two different types of statins over the observational
period of 2 years were excluded (n = 5,361). The control
group (non-statin-treated patients) consisted of patients to
whom no statins were dispensed during the observation
period. Antidepressant use was measured as the dispensing of
at least one antidepressant (ATC code starting with N06A)
or in combination with psycholeptics (N06CA), olanzapine
(N05AH03), quetiapine (N05AH04), sulpiride (N05AL01),
lithium (N05AN01), or benzodiazepine derivatives (N05BA)
during the observation period.
Finally, the following groups were defined and compared:
1) Statin-treated patients vs. non-statin-treated patients.
2) Sub-analysis (independent of inpatient care): statin-treated
patients on antidepressant medication vs. non-statin-treated
patients on antidepressant medication.
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Average Daily Doses
Average daily doses for the drugs were calculated from the
prescribed dosage, which was converted from defined daily dose
to mg and divided by the number of days that were not spent in
a hospital. To obtain the individual averages of the daily doses,
we extracted the individual drug histories, including information
on dates of received prescriptions and the corresponding dosage
of the prescribed statin. The average was calculated by dividing
the sum of all amounts of the administered drug by the sum of
treatment days, minus the days a patient spent in hospital. The
hospital days were subtracted on the assumption that the patients
were treated with statins during the hospital stay.
In order to ensure precise characterization and interpretation
of each substance, we defined groups according to the average
daily dose for each statin, resulting in the following categories:
>0–10mg, >10–20mg, >20–40mg, >40–60mg, >60–80 mg.
Ethical Approval
This study has been approved by the ethics commission
of the Medical University of Vienna (EK-Nr.: 1020/2020).
A detailed statement on ethical approval is provided in
the Supplementary Material. Written informed consent
from the patients was not required to participate in this
study in accordance with the national legislation and the
institutional requirements.
Statistical Analysis
We calculated odds ratios (ORs) between each case of statin use
and diagnosis of MDD in a matched cohort analysis (each statin-
treated patient was matched to three members of the control
group of the same age and sex). Weighted multiple logistic
regression, as described in similar analysis designs (31), was
used to investigate this association while controlling for age,
sex, dosage, and prescription of other medications (for diabetes
and fibrates).
Patients were assigned a categorical variable for each statin
comprising the respective average daily dose in mg. We
controlled for use of other medications (at least four different
quarters during which 20 different glucose-lowering drugs were
dispensed, including metformin; three fibrates) by introducing
binary dummy variables. Model quality was evaluated using the
adjusted R-squared statistic, multi-collinearity via the variance
inflation factor (VIF). Stratification was used to control for
other diagnoses potentially associated with statin use and MDD
and which could in principle act as confounding factors.
These robustness tests excluded all patients with a diagnosis
of ischaemic heart diseases (any code from the range I20–
I25), diseases of the arteries, including arterioles and capillaries
(I70–I79), stroke (I63–I64), diabetes (E10–E11), obesity (E66),
hypothyroidism (E02–E03), cancer (any code from the range
C00–C97), dementia in Alzheimer’s disease (specific ICD code
for patients with Alzheimer’s disease additionally diagnosed with
dementia) and Alzheimer’s disease (F00, G30), pain (R52), and
sleep disorder (G47). Statistical analysis was performed using
standard packages of Matlab.
RESULTS
Of a total of 7,481,168 patients, 84,638 (1.13% of the general
Austrian population) were diagnosed with MDD during a
hospital stay and 888,596 (11.88% of the general Austrian
population) were undergoing antidepressant therapy (prescribed
independently of a hospital stay). The baseline characteristics of
statin-treated patients and their age- and sex-matched control
group are described in Table 1. In general, statin-treated patients
(males and females) weremore likely to have been diagnosed with
MDD and were more commonly treated with antidepressants
when compared to age- and sex-matched non-statin treated
patients (OR: 1.54, CI: 1.53–1.56).
Supplementary Table 1 shows the baseline characteristics
of the statin-treated patients with diagnosed MDD in
comparison to patients with MDD without statin treatment.
Depressed patients undergoing statin treatment often received
antidepressant and antidiabetic therapy and displayed a
higher prevalence rate of CVD, stroke, diseases of the arteries,
overweight, obesity and hypothyroidism than those without
statin treatment.
Dose-Dependence of Statins on Diagnosis
of MDD
In the general population there was an increased risk of
diagnosis with depression in statin-treated patients when
compared to matched controls (OR: 1.22, CI: 1.20–1.25).
Further, there was a potency- and dose-dependent relationship
between statins and diagnosis of MDD (see Table 2, Figure 1,
Supplementary Figures 2, 3 for multiple logistic regression
analyses and odds of diagnosis). In comparison to non-statin-
treated patients, there was an underrepresentation of diagnosed
MDD in patients receiving lovastatin in doses of >0–20mg
(0–10 mg: OR: 0.12, 95% CI: 0.05–0.27; 10–20 mg: OR: 0.62,
95% CI: 0.41–0.95). Similar results were observed for pravastatin
>0–20mg (0–10 mg: OR: 0.36, 95% CI: 0.29–0.44; 10–20 mg:
OR: 0.63, CI: 0.56–0.70), simvastatin >0–20mg (0–10 mg:
OR: 0.59, 95% CI: 0.54–0.64; 10–20 mg: OR: 0.81, CI: 0.77–
0.86), atorvastatin >0–10mg (OR: 0.65, 95% CI: 0.59–0.70),
rosuvastatin >0–10mg (OR: 0.68, 95% CI: 0.53–0.85) and
fluvastatin >10–60mg. The results in Table 2 also demonstrate
that the lower risk of diagnosis with MDD in low-dose statin-
treated patients decreased with an increase in the potencies
of statins. The OR increased with potency, the lowest OR
beginning in lovastatin-treated patients. Although there was
an underrepresentation of diagnosed MDD in low-dose statin
treatment, the higher dosages showed an overrepresentation of
MDD. Dosages of >20mg of simvastatin (20–40 mg: OR: 1.28,
95% CI: 1.21–1.35; 40–60 mg: OR: 2.42, 95% CI: 2.18–2.70;
60–80 mg: OR: 5.27, 95% CI: 4.21–6.60), >10mg atorvastatin
(10–20 mg: OR: 1.19, 95% CI: 1.06–1.33; 20–40 mg: OR: 1.91,
95% CI: 1.60–2.27;40–60 mg: OR: 2.71, 95% CI: 1.98–3.72; 60–
80 mg: OR: 3.73, 95% CI: 2.22–6.28) and rosuvastatin >20mg
(20–40 mg: OR: 2.09, 95% CI: 1.31–3.34) were related to an
overrepresentation of MDD when compared to controls without
statin treatment.
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TABLE 1 | Baseline characteristics of the study population, showing group size, age and the absolute and relative frequencies of depression, use of other medications
(insulin, oral antidiabetics, antidepressants) and comorbid conditions for males and females in the statin-treated and in the matched control group.
Statin-treated patients Non-statin-treated patients
Male Female Male Female
N 166,979 170,259 500,937 510,777
Age (mean +/– SD) 64.91 +/- 10.86 68.88 +/– 10.41 64.91 +/– 10.86 68.88 +/– 10.41
Depression (F32–F33) 2,947* (1.76%) 6,774* (3.98%) 6,907 (1.38%) 15,953 (3.12%)
Antidepressants 35,379* (21.19%) 63,534* (37.32%) 73,675 (14.71%) 140,846 (27.57%)
Insulin 10,697* (6.41%) 11,348* (6.67%) 6,281 (1.25%) 6,296 (1.23%)
Oral antidiabetics 32,639* (19.55%) 30,950* (18.18%) 26,605 (5.31%) 25,462 (4.98%)
CVD (I20-I25) 32,611* (19.53%) 20,803* (12.22%) 21,733 (4.34%) 19,631 (3.84%)
Stroke (I63, I64) 4,367* (2.62%) 3,684* (2.16%) 5,826 (1.16%) 5,860 (1.15%)
Diseases of arteries (I70–I79) 10,552* (6.32%) 7,569* (4.45%) 13,227 (2.64%) 10,415 (2.04%)
Overweight and obesity (E66) 7,164* (4.29%) 7,149* (4.20%) 8,384 (1.67%) 11,061 (2.17%)
Hypothyroidism (E02, E03) 1,239* (0.74%) 3,277* (1.92%) 2,551 (0.51%) 6,735 (1.32%)
Alzheimer’s disease (F00, G30) 547* (0.33%) 990* (0.58%) 2,537 (0.51%) 4,381 (0.86%)
Pain (R52) 195* (0.12%) 302 (0.18%) 732 (0.15%) 1,003 (0.20%)
Sleep disorders (G47) 2,806* (1.68%) 951* (0.56%) 4,624 (0.92%) 1,878 (0.37%)
SD, standard deviation; CVD, cardiovascular disease, Asterisks denote statistically significant differences between statin- and non-statin treated patients; **p < 0.01, *p < 0.05.
TABLE 2 | Dose-dependent relationship between statins and diagnosis of depression.
All Lovastatin Fluvastatin Pravastatin Simvastatin Atorvastatin Rosuvastatin
>0–10mg 0.12** 1.00 0.36** 0.59** 0.65** 0.68**
CI 0.05–0.27 1.00–1.00 0.29–0.44 0.54–0.64 0.59–0.70 0.53–0.85
>10–20mg 0.62* 0.59** 0.63** 0.81** 1.19** 1.20
CI 0.41–0.95 0.43–0.81 0.56–0.70 0.77–0.86 1.06–1.33 0.95–1.53
>20–40mg 1.29 0.70** 1.02 1.28** 1.91** 2.09**
CI 0.66–2.51 0.62–0.79 0.91–1.15 1.21–1.35 1.60–2.27 1.31–3.34
>40–60mg 0.77** 2.42** 2.71**
CI 0.68–0.86 2.18–2.70 1.98–3.72
>60–80mg 1.13 5.27** 3.73**
CI 0.97–1.31 4.21–6.60 2.22–6.28
Adj. R∧2 0.99 0.98 0.98 0.98 0.99 0.99
Max. VIF 1,61 1.52 1.51 1.93 1.63 1.62
**p < 0.01; *p < 0.05.
Bold values represent the significant ORs.
Robustness Test for Diseases Commonly
Related to MDD
We further conducted a robustness test to estimate the
influence of diseases directly related to MDD, in particular
ischemic heart disease, diseases of arteries, stroke, diabetes,
obesity, hypothyroidism, cancer, dementia in Alzheimer’s disease,
Alzheimer’s disease, pain, and sleep disorders. We thus
tested whether the dosage-dependent MDD risk trajectories
are independent of the above-mentioned disease groups
(see Figure 2, Supplementary Material: baseline tests and
Supplementary Figures 5–10). In these robustness tests the
results showed that the observed dose dependencies followed
the same trend, with an underrepresentation of diagnosed
MDD in low-dose and an overrepresentation in high-dose
statin-treatment. The dose-dependent relationship could also
be observed in a sub-analysis that only included patients
hospitalized at least once (see Supplementary Figure 1).
Sex-Specific Analysis of the
Dose-Dependent Relationship Between
Statins and Diagnosis of MDD
In both male and female patients, the results shown in the
general population were confirmed, demonstrating that low-
dose statin treatment is related to underrepresentation of
diagnosed MDD whereas high-dose statin treatment is related
to overrepresentation when compared to non-statin-treated
patients. Especially for high-dose atorvastatin treatment, we
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FIGURE 1 | Dose-dependent relationship between (A) simvastatin (n = 214,021), (B) atorvastatin (n = 37,919), (C) and rosuvastatin (n = 8,209) and diagnosis of
depression obtained from the logistic regression model.
found that the risk of diagnosis with MDD in females was
nearly double than in males. Further details can be found in
Supplementary Tables 2, 3, Supplementary Figure 4.
Sub-Analysis—Dose-Dependent
Relationship Between Statin Treatment
and Antidepressant Therapy
The final sub-analysis included 888,596 patients receiving
antidepressant medication prescribed independently of
hospitalization. Statin treatment was recorded for 98,913 of
these patients. In the sub-analysis of all patients treated with
antidepressants, similar dose-dependent results in statin-treated
patients could be observed. Thus, low-dose statin treatment was
related to an underrepresentation and high-dose statin treatment
to an overrepresentation of antidepressant medication when
compared to non-statin-treated patients (Figure 3).
DISCUSSION
In the present study, we investigated the relationship between
different types and dosages of statins and diagnosis of MDD
in comparison to non-statin-treated patients. We were able
to demonstrate that there was an increased risk of diagnosed
MDD in patients treated with higher doses of statins when
compared to non-statin-treated patients. Interestingly, low-dose
statin treatment was related to an underrepresentation of MDD
when compared to non-statin-treated patients. Our findings are
also supported by sex-specific results and displayed no qualitative
change after exclusion of patients with diseases closely related
to diagnosis of MDD, such as cardiovascular disease or diabetes,
and to statin use. The dose-dependent results were also observed
in a sub-analysis only including patients taking antidepressant
medication prescribed independently of hospitalization.
Given the physiological mechanisms associated with statins,
a relationship between statin treatment and mood disorders
such as MDD seems plausible. Statins inhibit HMG-CoA
reductase, which is the main mechanism for the synthesis
of cholesterol, resulting in lower cholesterol levels (32) and
consequently subsequent products such as sex hormones (2–5).
Close relationships between low sex hormone levels and
mood disorders were also suggested (7, 9, 11, 12). We have
recently published evidence for a dose-dependent increased
risk of diagnosis of osteoporosis in statin-treated patients and
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FIGURE 2 | Dose-dependent relationship between (A) simvastatin, (B) atorvastatin, and (C) rosuvastatin and diagnosis of depression for baseline (all statin-treated
patients) and after the exclusion of patients with cardiovascular disease (I20–I25, n = 53,414) and (n = 71,722)/or diabetes (E10–E11, n = 32,815) obtained from the
logistic regression model.
hypothesized that specifically higher dosages could inhibit the
synthesis of sex hormones on a clinically relevant level and
therefore advance bone resorption (33). By showing that there
is also a dose-dependent relationship with diagnosed MDD, here
we demonstrate for the first time that it is important to consider
the different types of statins and their dosages when investigating
the relationship between statin treatment and diagnosis of MDD.
Concerns about potential central nervous side-effects of
statins have been raised for almost 30 years. A series of pioneering
work made a case for increased depression rates as well as
non-cardiovascular mortality due to violent incidents and suicide
in patients with low cholesterol and thus in statin users (34–39).
Interestingly, these early positive associations were rarely
replicated (17), as more recent large clinical and register-based
studies have generally implied no increased risk of developing
MDD in statin users (22). On the contrary, protective effects
have been reported and were related to neuroinflammation as
a potential key mechanism of depression (40–42). Nevertheless,
overall the mechanisms of putative association in either direction
are insufficiently understood. Most importantly, the majority of
studies have neglected different potencies and dosages of statins
despite recent advances linking statins with high lipophilia and
hence permeability of the blood-brain barrier but not establishing
a connection between hydrophilic statins and MDD (43). Hence
it is not clear whether under high-dose statin therapy a stronger
downregulation of sex hormones, which are closely related to
MDD, could possibly overrule the positive anti-inflammatory
effect of statins on MDD.
Data regarding the dose-dependent risk of MDD in statin-
treated patients are particularly sparse. For instance, in placebo-
controlled clinical trials it has been shown that both low-
dose lovastatin treatment (30mg) (44) and low-dose simvastatin
treatment (20mg) (45, 46) resulted in significant relief of
depressive symptoms. There are also other prospective studies
demonstrating that low-dose statin treatment, such as 20mg of
atorvastatin (46, 47), could have positive effects on symptoms of
depression. These results indicate that low-dose statin treatment
could indeed be effective in the treatment of depression and
are consequently in accordance with our results, as we found
an underrepresentation of MDD in patients treated with lower
doses of lovastatin (0–20mg), pravastatin (0–20mg), simvastatin
(0–20mg), atorvastatin (0–10mg), and rosuvastatin (0–10mg).
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FIGURE 3 | Dose-dependent relationship between (A) simvastatin, (B) atorvastatin, and (C) rosuvastatin and antidepressant medication (n = 98,913) obtained from
the logistic regression model.
There is evidence that statins can have positive effects on
depression via an anti-inflammatory effect, modulation of
cytokines and reduction of oxidative stress. Improved quality
of life due to improved health consciousness and treatment
compliance and reduced cardiovascular risk has also been linked
to a potential antidepressant effect of statins (48). Nevertheless,
especially the relationship to higher dosages has yet to be
investigated sufficiently. That it is also important to investigate
the different types of statins with their different potencies has
been demonstrated by a Swedish national cohort study showing
that simvastatin had a protective effect on depression, whereas
atorvastatin treatment increased the risk. However, there was no
detailed investigation of different dosages (25).
In the present study, higher dosages were related to an
overrepresentation of MDD in statin-treated patients. These
results could be confirmed by a sex-specific analysis and remain
unchanged after exclusion of patients with diseases closely
related to MDD. Further, similar results were observed in
a sub-analysis investigating all patients taking antidepressant
medication prescribed independently of hospitalization. Thus,
dosage and potency may be the deciding factors for protective
or risk-increasing effects. Whether a possible downregulation
of hormones directly related to MDD under high-dose
statin treatment could overwhelm the described positive anti-
inflammatory effects of statins on MDD should be investigated
in larger prospective clinical trials. The overrepresentation of
diagnosed MDD in high-dose statin-treated patients is of special
interest with regard to the synthesis and processing of cholesterol
to essential hormones such as steroid hormones or Vitamin D. A
study by Chan et al. investigated the effect of high-dose 80mg
simvastatin therapy on mood in a cohort of 140 patients with
secondary progressive multiple sclerosis by conducting a 24
month, double-blind controlled trial. They showed similar results
to those of our study, namely that high-dose statin treatment
was related to increased severity of depressive symptoms, as
measured using the Hamilton Depression Rating Scale (HAM-D)
(49). Hence the fact that cholesterol is required for the serotonin
1A receptor to function (18–20) also has to be considered,
since down-regulation of this receptor is closely related to mood
disorders (21).
Possible interactions with the metabolization of statins should
not be discounted either, as in our study females were at
over double the risk of diagnosis with MDD than males when
receiving high-dose atorvastatin treatment. One thus has to
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consider that atorvastatin is metabolized by cytochrome P450
3A4 (CYP3A4), which is also involved in the metabolism
of estrogens.
Our study has both limitations and strengths. First, register-
based studies are limited by the fact that there is no opportunity
to precisely characterize the diagnosis of the diseases using
clinical data, since we only have access to ICD codes. In the
present study, the number of patients diagnosed with depression
was in relation to the actual literary lower. However, a strength is
that antidepressant medication was also recorded independently
of hospital stays and this number reflects the actual literary
and might compensate underreporting in the second group.
A further limitation of the present study is that we do not
have information on the duration of statin treatment and that
we cannot infer causal effects using the cross-sectional study
design. Additionally, it is not possible to screen the data for
potential associations between different time periods of statin
treatment and the relationship to major depressive disorders
and/or antidepressant medication. Hence especially high-dose
statin-treated patients often had a history of cardiovascular
events and a higher occurrence of cardiovascular risk markers
and thusMDD could therefore be a consequence of CVD (50, 51).
In our dataset from 2006 to 2007 we had no access to cholesterol
levels and could therefore only hypothesize that there could be a
dose dependent relationship between statins and the upcoming
synthesis of vital hormones (e.g., testosterone and estrogen),
which are directly related to MDD. Additionally, we have no
information on marital and socioeconomic status, which is also
related to MDD. Also, we have no information about common
side effects of statins, such as muscle symptoms or reduced
exercise tolerance, and it is known that these symptoms may
induce mood disorders. Further, it was not possible to provide
detailed analysis of treatment adherence. In comparison to
controls, statin-treated patients are characterized in the present
study by a higher rate of comorbidities and it is a well-known
fact that diseases such as diabetes mellitus or CHD, for instance,
are closely related to the development of MDD. However, in our
robustness tests, there was no qualitative change in the results
after the exclusion of patients with such diagnoses.
CONCLUSION
In conclusion, our results demonstrate that there exists a
dose-dependent relationship between statins and diagnosis of
MDD, substantiating both underrepresentation of MDD in
low-dose statin treatment and increased risk of diagnosis with
MDD in high-dose treatment. Considering the widespread use
of statins primarily for disease prevention and increasingly
stricter recommendations for tolerated cholesterol levels, these
findings may be highly relevant for clinical routine across a
broad spectrum of medical disciplines. This is an important
and interesting approach for precision medicine in particular.
Nevertheless, keeping in mind the limitations of register-
based studies, prospective and longitudinal trials are urgently
needed to validate our findings and further elucidate the
mechanisms involved.
DATA AVAILABILITY STATEMENT
The data is not available to access because this is a consolidated
research database that is only accessible for selected partners
under a strict data protection policy.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Medical University of Vienna. Written
informed consent for participation was not required for this
study in accordance with the national legislation and the
institutional requirements.
AUTHOR CONTRIBUTIONS
LM, MC, KA, KM, TS, KP, and K-WA: study design. LM, MC,
and KP: data analysis. LM and MC: manuscript writing. K-WA:
is the guarantor of this work. All authors read, reviewed, and
approved the final manuscript.
FUNDING
This study was funded by the Vienna Science and Technology
Fund (MA16-045).
ACKNOWLEDGMENTS
We extend our thanks to Dr. Gottfried Endel for his assistance
with data assessment.
SUPPLEMENTARY MATERIAL




1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L,
et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:
lipid modification to reduce cardiovascular risk. Eur Heart J. (2019)
41:111–88. doi: 10.15829/1560-4071-2020-3826
2. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect
of statins on testosterone in men and women, a systematic review
and meta-analysis of randomized controlled trials. BMC Med. (2013)
11:57. doi: 10.1186/1741-7015-11-57
3. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is
associated with lower total but not bioavailable or free testosterone in
men with type 2 diabetes. Diabetes Care. (2009) 32:541–6. doi: 10.2337/dc0
8-1183
4. Corona G, Boddi V, Balercia G, Rastrelli G, De Vita G, Sforza
A, et al. The effect of statin therapy on testosterone levels in
Frontiers in Medicine | www.frontiersin.org 8 February 2021 | Volume 8 | Article 608083
Michael et al. Statins and Major Depressive Disorder
subjects consulting for erectile dysfunction. J Sex Med. (2010)
7(Pt.1):1547–56. doi: 10.1111/j.1743-6109.2009.01698.x
5. Zhang X, Li J, Zhou X, Guan Q, Zhao J, Gao L, et al. Simvastatin
decreases sex hormone levels in male rats. Endocr Pract. (2017)
23:175–81. doi: 10.4158/EP161274.OR
6. Newhouse P, Albert K. Estrogen, stress, and depression:
a neurocognitive model. JAMA Psychiatry. (2015)
72:727–9. doi: 10.1001/jamapsychiatry.2015.0487
7. Schmidt PJ, Ben Dor R, Martinez PE, Guerrieri GM, Harsh VL, Thompson
K, et al. Effects of estradiol withdrawal on mood in women with past
perimenopausal depression: a randomized clinical trial. JAMA Psychiatry.
(2015) 72:714–26. doi: 10.1001/jamapsychiatry.2015.0111
8. Xu Y, Sheng H, Bao Q, Wang Y, Lu J, Ni X. NLRP3 inflammasome
activation mediates estrogen deficiency-induced depression- and anxiety-like
behavior and hippocampal inflammation in mice. Brain Behav Immun. (2016)
56:175–86. doi: 10.1016/j.bbi.2016.02.022
9. Almeida OP, Lautenschlager N, Vasikaram S, Leedman P, Flicker L.
Association between physiological serum concentration of estrogen
and the mental health of community-dwelling postmenopausal
women age 70 years and over. Am J Geriatr Psychiatry. (2005)
13:142–9. doi: 10.1097/00019442-200502000-00008
10. Holsen LM, Spaeth SB, Lee JH, Ogden LA, Klibanski A, Whitfield-Gabrieli
S, et al. Stress response circuitry hypoactivation related to hormonal
dysfunction in women with major depression. J Affect Disord. (2011)
131:379–87. doi: 10.1016/j.jad.2010.11.024
11. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR.
Increased incidence of diagnosed depressive illness in hypogonadal oldermen.
Arch Gen Psychiatry. (2004) 61:162–7. doi: 10.1001/archpsyc.61.2.162
12. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and
depression: systematic review and meta-analysis. J Psychiatr Pract. (2009)
15:289–305. doi: 10.1097/01.pra.0000358315.88931.fc
13. McHenry J, Carrier N, Hull E, Kabbaj M. Sex differences in anxiety
and depression: role of testosterone. Front Neuroendocrinol. (2014)
35:42–57. doi: 10.1016/j.yfrne.2013.09.001
14. Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee
DE. Higher prevalence of depressive symptoms in middle-aged
men with low serum cholesterol levels. Psychosom Med. (2000)
62:205–11. doi: 10.1097/00006842-200003000-00009
15. Tomson-Johanson K, Harro J. Low cholesterol, impulsivity and
violence revisited. Curr Opin Endocrinol Diabetes Obes. (2018)
25:103–7. doi: 10.1097/MED.0000000000000395
16. Morales K, Wittink M, Datto C, DiFilippo S, Cary M, TenHave T, et al.
Simvastatin causes changes in affective processes in elderly volunteers. J Am
Geriatr Soc. (2006) 54:70–6. doi: 10.1111/j.1532-5415.2005.00542.x
17. Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin
affect mood and steroid hormone levels in hypercholesterolemic men?
A randomized double-blind trial. Psychoneuroendocrinology. (2003)
28:181–94. doi: 10.1016/S0306-4530(02)00014-8
18. Jafurulla M, Chattopadhyay A. Membrane lipids in the function
of serotonin and adrenergic receptors. Curr Med Chem. (2013)
20:47–55. doi: 10.2174/0929867311302010006
19. Jafurulla M, Rao BD, Sreedevi S, Ruysschaert JM, Covey DF, Chattopadhyay
A. Stereospecific requirement of cholesterol in the function of
the serotonin1A receptor. Biochim Biophys Acta. (2014) 1838(Pt.
B):158–63. doi: 10.1016/j.bbamem.2013.08.015
20. Pucadyil TJ, Chattopadhyay A. Role of cholesterol in the function and
organization of G-protein coupled receptors. Prog Lipid Res. (2006)
45:295–333. doi: 10.1016/j.plipres.2006.02.002
21. Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin-
1A receptor alterations in depression: a meta-analysis of molecular imaging
studies. BMC Psychiatry. (2016) 16:319. doi: 10.1186/s12888-016-1025-0
22. Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins
for the treatment of depression: a meta-analysis of randomized,
double-blind, placebo-controlled trials. J Affect Disord. (2016)
200:235–42. doi: 10.1016/j.jad.2016.04.047
23. Chuang CS, Yang TY, Muo CH, Su HL, Sung FC, Kao CH.
Hyperlipidemia, statin use and the risk of developing depression: a
nationwide retrospective cohort study. Gen Hosp Psychiatry. (2014)
36:497–501. doi: 10.1016/j.genhosppsych.2014.05.008
24. Kim SW, Bae KY, Kim JM, Shin IS, Hong YJ, Ahn Y, et al. The use of statins for
the treatment of depression in patients with acute coronary syndrome. Transl
Psychiatry. (2015) 5:e620. doi: 10.1038/tp.2015.116
25. Redlich C, Berk M,Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and
risk of depression: a Swedish national cohort study. BMC Psychiatry. (2014)
14:348. doi: 10.1186/s12888-014-0348-y
26. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk
of depression and suicidal behavior. Arch Intern Med. (2003)
163:1926–32. doi: 10.1001/archinte.163.16.1926
27. O’Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ, et al.
The impact of statins on psychological wellbeing: a systematic review and
meta-analysis. BMCMed. (2012) 10:154. doi: 10.1186/1741-7015-10-154
28. Parsaik AK, Singh B, Murad MH, Singh K, Mascarenhas SS, Williams MD,
et al. Statins use and risk of depression: a systematic review and meta-analysis.
J Affect Disord. (2014) 160:62–7. doi: 10.1016/j.jad.2013.11.026
29. Stafford L, Berk M. The use of statins after a cardiac intervention is
associated with reduced risk of subsequent depression: proof of concept for
the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry.
(2011) 72:1229–35. doi: 10.4088/JCP.09m05825blu
30. Kohler-Forsberg O, Otte C, Gold SM, Ostergaard SD. Statins in
the treatment of depression: hype or hope? Pharmacol Ther. (2020)
215:107625. doi: 10.1016/j.pharmthera.2020.107625
31. Kautzky-Willer A, Thurner S, Klimek P. Use of statins offsets insulin-related
cancer risk. J Intern Med. (2017) 281:206–16. doi: 10.1111/joim.12567
32. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-
CoA reductase. Science. (2001) 292:1160–4. doi: 10.1126/science.1059344
33. Leutner M,Matzhold C, Bellach L, Deischinger C, Harreiter J, Thurner S, et al.
Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann
Rheum Dis. (2019) 78:1706–11. doi: 10.1136/annrheumdis-2019-215714
34. MuldoonMF,Manuck SB,Matthews KA. Lowering cholesterol concentrations
and mortality: a quantitative review of primary prevention trials. BMJ. (1990)
301:309–14. doi: 10.1136/bmj.301.6747.309
35. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing
serum cholesterol. BMJ. (1994) 308:373–9. doi: 10.1136/bmj.308.6925.373
36. Boumendil E, Tubert-Bitter P. Depression-induced absenteeism in relation
to antihyperlipidemic treatment: a study using GAZEL cohort data.
Epidemiology. (1995) 6:322–5. doi: 10.1097/00001648-199505000-00023
37. Ploeckinger B, Dantendorfer K, Ulm M, Baischer W, Derfler K, Musalek
M, et al. Rapid decrease of serum cholesterol concentration and postpartum
depression. BMJ. (1996) 313:664. doi: 10.1136/bmj.313.7058.664
38. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report
of the conference on low blood cholesterol: mortality associations.Circulation.
(1992) 86:1046–60. doi: 10.1161/01.CIR.86.3.1046
39. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality:
the importance of considering initial level of risk. BMJ. (1993)
306:1367–73. doi: 10.1136/bmj.306.6889.1367
40. Kohler O, Krogh J, Mors O, Benros ME. Inflammation in depression and
the potential for anti-inflammatory treatment. Curr Neuropharmacol. (2016)
14:732–42. doi: 10.2174/1570159X14666151208113700
41. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW,
Krogh J, et al. Autoimmune diseases and severe infections as risk
factors for mood disorders: a nationwide study. JAMA Psychiatry. (2013)
70:812–20. doi: 10.1001/jamapsychiatry.2013.1111
42. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL,
Mors O, et al. Effect of anti-inflammatory treatment on depression,
depressive symptoms, and adverse effects: a systematic review and
meta-analysis of randomized clinical trials. JAMA Psychiatry. (2014)
71:1381–91. doi: 10.1001/jamapsychiatry.2014.1611
43. Dave CV, Winterstein AG, Park H, Cook RL, Hartzema AG. Comparative risk
of lipophilic and hydrophilic statins on incident depression: a retrospective
cohort study. J Affect Disord. (2018) 238:542–6. doi: 10.1016/j.jad.2018.06.021
44. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with
lovastatin for treating major depressive disorder, a randomized
double-blind placebo controlled-clinical trial. Depress Anxiety. (2013)
30:1084–8. doi: 10.1002/da.22195
Frontiers in Medicine | www.frontiersin.org 9 February 2021 | Volume 8 | Article 608083
Michael et al. Statins and Major Depressive Disorder
45. Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour
N, et al. Simvastatin as an adjuvant therapy to fluoxetine in patients with
moderate to severe major depression: A double-blind placebo-controlled trial.
J Psychopharmacol. (2015) 29:575–81. doi: 10.1177/0269881115578160
46. Abbasi SH, Mohammadinejad P, Shahmansouri N, Salehiomran A, Beglar
AA, Zeinoddini A, et al. Simvastatin vs. atorvastatin for improving mild
to moderate depression in post-coronary artery bypass graft patients: A
double-blind, placebo-controlled, randomized trial. J Affect Disord. (2015)
183:149–55. doi: 10.1016/j.jad.2015.04.049
47. Haghighi M, Khodakarami S, Jahangard L, Ahmadpanah M, Bajoghli H,
Holsboer-Trachsler E, et al. In a randomized, double-blind clinical trial,
adjuvant atorvastatin improved symptoms of depression and blood lipid
values in patients suffering from severe major depressive disorder. J Psychiatr
Res. (2014) 58:109–14. doi: 10.1016/j.jpsychires.2014.07.018
48. Molero Y, Cipriani A, Larsson H, Lichtenstein P, D’Onofrio BM, Fazel S.
Associations between statin use and suicidality, depression, anxiety, and
seizures: a Swedish total-population cohort study. Lancet Psychiatry. (2020)
7:982–90. doi: 10.1016/S2215-0366(20)30311-4
49. Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, et al. Effect
of high-dose simvastatin on cognitive, neuropsychiatric, and health-related
quality-of-lifemeasures in secondary progressivemultiple sclerosis: secondary
analyses from the MS-STAT randomised, placebo-controlled trial. Lancet
Neurol. (2017) 16:591–600. doi: 10.1016/S1474-4422(17)30113-8
50. Tang B, Yuan S, Xiong Y, He Q, Larsson SC. Major depressive disorder
and cardiometabolic diseases: a bidirectional Mendelian randomisation study.
Diabetologia. (2020) 63:1305–11. doi: 10.1007/s00125-020-05131-6
51. Luijendijk HJ, Tiemeier H, van den Berg JF, Bleumink GS, Hofman
A, Stricker BH. Heart failure and incident late-life depression. J
Am Geriatr Soc. (2010) 58:1441–8. doi: 10.1111/j.1532-5415.2010.02
921.x
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Michael, Caspar, Alexander, Michaela, Stefan, Peter and
Alexandra. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Medicine | www.frontiersin.org 10 February 2021 | Volume 8 | Article 608083
